Author: HERVolution Therapeutics

HERVolution Therapeutics Presents Clinical Evidence of HERV-K Driving Metabolic Senescence at the International Congress on Obesity 2026

July 15, 2026
HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen

June 10, 2026

HERVolution Therapeutics Presents Clinical Evidence of HERV-K Driving Metabolic Senescence at the International Congress on Obesity 2026